The most effective anti-aging drug ever tested on a mammal was not invented in a laboratory. It was scraped out of the dirt of a Pacific island in 1964 by a Hungarian-Canadian microbiologist who was actually looking for something else entirely. The chemistry that made rapamycin’s discovery possible was, by the standards of 1960s pharmaceutical research, routine. The active compound is produced by a bacterium called Streptomyces hygroscopicus — a member of a genus of soil-dwelling actinomycetes that had, by the mid-20th century, been recognised as the most productive single source of clinically useful antibiotics in nature. Streptomyces species had already given the world streptomycin (1943), chloramphenicol (1947), neomycin (1949), tetracycline (1953), vancomycin (1953), and gentamicin (1963), among others. Pharmaceutical companies of the period maintained active programmes for collecting soil samples from geographically unusual locations on the assumption that previously uncharacterised Streptomyces strains might yield additional useful compounds. Nógrády’s Easter Island samples were one such collection. They were stored, characterised, and analysed at Ayerst across the late 1960s and early 1970s under the supervision of a small team that included the Pakistani-born Indian-Canadian biochemist Suren Sehgal, who would, in the subsequent four decades, become substantially the most important individual scientific advocate for the compound the Easter Island soil had produced.
According to an Impact Journals reconstruction of rapamycin’s full discovery history and its subsequent development as a pharmacological intervention, the compound itself was first isolated from the Easter Island soil samples in 1972, with the initial published characterisation appearing in 1975 in the Journal of Antibiotics under the lead authorship of the Ayerst chemist Claude Vézina. Sehgal proposed the name “rapamycin,” combining the indigenous Rapa Nui name for the island with the standard “-mycin” suffix used for actinomycete-derived antibiotics. The compound was initially developed as an antifungal agent. It did not work particularly well as an antifungal agent. Ayerst, by the late 1970s, was preparing to abandon the rapamycin programme entirely as a commercial failure. Sehgal, in a story that has subsequently become part of the standard mythology of the longevity-research community, removed several vials of the compound from the Ayerst freezers in 1982 and stored them in his home freezer in suburban Montreal — at his own expense, on his own responsibility, against the explicit wishes of his employer — on the grounds that the compound seemed to him too interesting to discard. When Ayerst was acquired by Wyeth in 1988, Sehgal retrieved his vials from the home freezer and persuaded the new corporate parent to fund a renewed research programme. The result, between 1989 and 1999, was the development of rapamycin as an immunosuppressive drug capable of preventing organ transplant rejection — for which the FDA approved it under the trade name Rapamune in 1999.
The accidental anti-aging discovery
The mechanism by which rapamycin produces its immunosuppressive effect was, in the late 1990s, also the subject of substantial independent academic research at universities and institutes that had become interested in the compound for entirely different reasons. The protein complex that rapamycin inhibits, identified by researchers at the Whitehead Institute and elsewhere across the 1990s, was given the name “mechanistic target of rapamycin” (mTOR) in honour of the drug that had revealed its existence. As described in a 2016 paper in the journal Aging summarising rapamycin’s place in the broader trajectory of mTOR research, the mTOR pathway turned out to be one of the central regulatory mechanisms governing cellular growth, metabolism, protein synthesis, and the broader process by which cells respond to nutrient availability across essentially all eukaryotic organisms — from yeast and worms through flies and mice to humans. mTOR is, in essential respects, the cellular sensor of nutritional abundance. When nutrients are plentiful, mTOR signalling promotes growth, division, and the accumulation of cellular biomass. When nutrients are scarce, mTOR signalling decreases and cells switch into a maintenance and repair mode.
The connection to ageing emerged from a parallel research literature on caloric restriction. Studies dating to the 1930s had demonstrated that laboratory rodents fed approximately 30 percent fewer calories than their ad libitum-fed siblings lived substantially longer and aged more slowly across essentially every measurable biomarker. The mechanism had remained obscure for several decades. By the early 2000s, multiple research groups had independently identified mTOR suppression as one of the central downstream pathways through which caloric restriction produced its anti-ageing effects. The implication was direct: if rapamycin pharmacologically inhibited the same pathway that caloric restriction inhibited nutritionally, then rapamycin might, in principle, produce the same ageing-related benefits without requiring the substantial reduction in caloric intake that most experimental animals tolerated poorly and that essentially no human population has ever sustained voluntarily.
What the mice actually did
The first major test of the hypothesis in mammals was a study published in Nature in 2009 by a multi-institutional team coordinated through the National Institute on Aging’s Interventions Testing Program. The study was, by the standards of caloric-restriction research, methodologically unusual: it began rapamycin treatment in genetically diverse mice at 600 days of age — the mouse equivalent of approximately 60 human years, the period at which most experimental anti-ageing interventions have lost essentially all of their effectiveness. As reported by National Geographic’s coverage of the rapamycin anti-ageing literature and the human trials that have followed it, the results of the 2009 study were that rapamycin extended median lifespan in the treated mice by approximately 14 percent in females and 9 percent in males, and extended maximum lifespan — the figure that captures the upper boundary of what the species can achieve under any conditions — by approximately 14 percent overall. When the effect was measured instead as the increase in remaining life expectancy from the start of treatment at 600 days, the figure for female mice in that same 2009 ITP study reached approximately 38 percent — the metric that has been widely reported in the popular longevity literature, and that captures the practical impact of starting rapamycin treatment in already-elderly animals. Subsequent ITP studies have refined the dosing protocols and continued to demonstrate substantial lifespan extension across multiple genetically diverse mouse cohorts. No other pharmacological intervention tested in the same standardised programme has produced comparable results. The closest competitors — metformin, acarbose, 17α-estradiol — typically produce lifespan extensions in the range of 5 to 22 percent under optimal conditions.
The translation to human medicine has been substantially slower than the mouse data would suggest. Per IFLScience’s overview of rapamycin’s broader pharmaceutical trajectory and its current off-label use as an anti-ageing intervention, the substantial side effect profile of chronic rapamycin administration — immunosuppression, impaired wound healing, lipid abnormalities, diabetes-related metabolic effects, mouth sores, anaemia — has made the drug substantially less attractive as a daily medication than the lifespan-extension data alone would imply. Small-scale human trials by Joan Mannick and others have demonstrated that pulsed rapamycin dosing — much lower frequency than the daily regimen used for transplant patients — appears to substantially preserve the anti-ageing benefits while reducing the immunosuppression side effects. A community of high-profile off-label users, including the longevity-medicine physician and podcaster Peter Attia, has emerged across the late 2010s and 2020s. The FDA has not approved rapamycin for any anti-ageing indication. The largest formal human anti-ageing trials, including the PEARL trial completed in 2024, have produced equivocal results that the longevity research community continues to debate. The compound itself — discovered in a soil sample collected on the most remote inhabited island on Earth in 1964, stored in a Montreal biochemist’s home freezer through the 1980s, FDA-approved for transplant medicine in 1999, identified as a lifespan-extender in mice in 2009, and informally adopted by a small but growing community of human users in the 2020s — has remained, in every animal model that has been systematically tested, the most effective single pharmacological extender of mammalian lifespan that scientists have ever identified. Whether it will eventually demonstrate the same effect in humans, and whether the cumulative side effects across decades of administration will prove worth whatever lifespan benefit emerges, are questions that the next two decades of clinical research will substantially settle.
Editorial process
Space Daily articles are produced with AI assistance and reviewed by editorial staff before publication. See our editorial standards and masthead.